TPO and acute myeloid leukemia: Among them, TPO mimetics are the most attractive: however, though the use of romiplostim seemed promising in a randomized trial,10 there is still concern regarding the risk of MDS progression/AML evolution and warning in the label of all TPO mimetics.16 Eltrombopag has a different mechanism of action from romiplostim.